Pills for memory: The medications that define dementia care today

SaveHealth reports on advancements in dementia medications, highlighting new treatments that modify disease progression and improve patient quality of life. Read More

FDA Approves Subcutaneous Leqembi for Treatment of Early Alzheimer Disease

The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) ... Read More

FDA approves new Alzheimer's drug; Bucks Co. man discusses experience in clinical trial

PHILADELPHIA (WPVI) -- The Food & Drug Administration has approved a new drug for Alzheimer's Disease. It's the first in nearly twenty years but it comes with controversy and some experts advised ... Read More

Ascension offers new Alzheimer’s treatment, brings hope to Wisconsin patients

Ascension became the first provider in Wisconsin to administer Kisunla, a new FDA-approved drug for Alzheimer’s, which is covered by insurance. Read More

FDA Approves Subcutaneous Form of Eisai, Biogen's Alzheimer's Drug Leqembi for Maintenance Dosing

The subcutaneous version, dubbed Leqembi Iqlik, is approved as a maintenance treatment that can be used after an initial intravenous infusion regimen. Read More

Alzheimer’s Drugs Are Finally Tackling the Disease Itself. Here’s How

While our understanding of Alzheimer’s disease is far from complete, the latest therapies, and others in more than 100 clinical trials, offer new hope ... Read More

Controversial New Alzheimer’s Drugs Offer Hope—But at a High Cost

New Alzheimer’s drugs known as anti-amyloid therapies may slow disease progression—but they also carry serious risks, including brain bleeds and strokelike symptoms ... Read More

FDA Approves Subcutaneous Leqembi for Treatment of Early Alzheimer Disease

TUESDAY, Sept. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous ... Read More

FDA approves subcutaneous Leqembi for treatment of early Alzheimer's disease

The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase. Leqembi Iqlik is a subcutaneous ... Read More